Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Receivables - Other (2022 - 2026)

Invivyd's (IVVD) quarterly Receivables - Other came in at $461000.0 in Q2 2026, up 315.32% on a YoY basis from $111000.0 in Q2 2025, and down 31.8% quarter-over-quarter from $676000.0 in Q4 2025.

Analysis

Invivyd (IVVD) Receivables - Other (2022 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Receivables - Other for 5 consecutive years, with $461000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Receivables - Other rose 315.32% year-over-year to $461000.0; the trailing twelve-month figure through Jun 2026 stood at $461000.0 (up 315.32% YoY), and the FY2025 full-year result was $676000.0, up 157.03% from the prior year.
  • Receivables - Other declined to $461000.0 in Q2 2026 per IVVD's latest filing, from $676000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $933000.0 in Q4 2023 and bottomed at $111000.0 in Q2 2025.
  • Historically, Receivables - Other has averaged $518266.7 across 5 years, with a median of $474000.0 in 2023.
  • The sharpest annual moves came in 2025 and 2026: Receivables - Other slumped 82.63% in 2025, then soared 315.32% in 2026.
  • Over 5 years, Receivables - Other stood at $377000.0 in 2022, then surged by 147.48% to $933000.0 in 2023, then sank by 71.81% to $263000.0 in 2024, then soared by 157.03% to $676000.0 in 2025, then sank by 31.8% to $461000.0 in 2026.
  • According to Business Quant data, Receivables - Other over the past three periods registered $461000.0, $676000.0, and $282000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 461,000.00
Dec 31, 2025 676,000.00
Sep 30, 2025 282,000.00
Jun 30, 2025 111,000.00
Mar 31, 2025 192,000.00
Dec 31, 2024 263,000.00
Sep 30, 2024 460,000.00
Jun 30, 2024 639,000.00
Mar 31, 2024 875,000.00
Dec 31, 2023 933,000.00
Sep 30, 2023 713,000.00
Jun 30, 2023 474,000.00
Mar 31, 2023 533,000.00
Dec 31, 2022 377,000.00
Sep 30, 2022 785,000.00